JP2024542738A - 疼痛の治療のための組成物及び方法 - Google Patents

疼痛の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2024542738A
JP2024542738A JP2024532733A JP2024532733A JP2024542738A JP 2024542738 A JP2024542738 A JP 2024542738A JP 2024532733 A JP2024532733 A JP 2024532733A JP 2024532733 A JP2024532733 A JP 2024532733A JP 2024542738 A JP2024542738 A JP 2024542738A
Authority
JP
Japan
Prior art keywords
formula
sirna molecule
nucleotides
antisense strand
ribonucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532733A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023102488A5 (https=
JP2024542738A5 (https=
Inventor
マクドノー，ステファン，アイ．
ガラント－ベーム，コリー
ハスラー，マシュー
カーティス，ダニエル
ダ クルス ゴディーニョ，ブルーノ，ミゲル
Original Assignee
アタランタ セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アタランタ セラピューティクス，インコーポレーテッド filed Critical アタランタ セラピューティクス，インコーポレーテッド
Publication of JP2024542738A publication Critical patent/JP2024542738A/ja
Publication of JPWO2023102488A5 publication Critical patent/JPWO2023102488A5/ja
Publication of JP2024542738A5 publication Critical patent/JP2024542738A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
JP2024532733A 2021-12-01 2022-12-01 疼痛の治療のための組成物及び方法 Pending JP2024542738A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284957P 2021-12-01 2021-12-01
US63/284,957 2021-12-01
PCT/US2022/080764 WO2023102488A2 (en) 2021-12-01 2022-12-01 Compositions and methods for treatment of pain

Publications (3)

Publication Number Publication Date
JP2024542738A true JP2024542738A (ja) 2024-11-15
JPWO2023102488A5 JPWO2023102488A5 (https=) 2025-12-08
JP2024542738A5 JP2024542738A5 (https=) 2025-12-08

Family

ID=86613161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532733A Pending JP2024542738A (ja) 2021-12-01 2022-12-01 疼痛の治療のための組成物及び方法

Country Status (9)

Country Link
US (1) US20250109402A1 (https=)
EP (1) EP4441228A2 (https=)
JP (1) JP2024542738A (https=)
KR (1) KR20240131349A (https=)
CN (1) CN118632929A (https=)
AU (1) AU2022403005A1 (https=)
CA (1) CA3240948A1 (https=)
MX (1) MX2024006649A (https=)
WO (1) WO2023102488A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025108284A1 (en) * 2023-11-20 2025-05-30 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of sodium voltage-gated channel alpha subunit 9 (scn9a)
WO2025140551A1 (en) * 2023-12-29 2025-07-03 Neuro3 Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING NaV1.7 (SCN9A) -ASSOCIATED DISORDERS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033027A2 (en) * 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain

Also Published As

Publication number Publication date
WO2023102488A8 (en) 2023-08-10
EP4441228A2 (en) 2024-10-09
KR20240131349A (ko) 2024-08-30
MX2024006649A (es) 2024-08-15
US20250109402A1 (en) 2025-04-03
WO2023102488A3 (en) 2023-09-14
CN118632929A (zh) 2024-09-10
WO2023102488A2 (en) 2023-06-08
AU2022403005A1 (en) 2024-07-11
CA3240948A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
WO2024073618A2 (en) Sirna compositions and methods targeting microtubule associated protein tau nucleic acids
JP2024542738A (ja) 疼痛の治療のための組成物及び方法
JP2025532885A (ja) 神経変性疾患の処置のための組成物及び方法
JP2025531483A (ja) 神経炎症疾患の治療のための組成物及び方法
JP2025532886A (ja) 神経疾患の処置のための組成物及び方法
EP4413136A1 (en) Compositions and methods for treatment of prion diseases
JP2025531484A (ja) 神経炎症性疾患の処置のための組成物及び方法
JP2024542728A (ja) てんかんの治療のための組成物及び方法
JP2025531481A (ja) 脊髄小脳変性症の治療のための組成物及び方法
JP2025517341A (ja) マイクロサテライトｄｎａ伸長疾患を治療するための組成物及び方法
JP2026509929A (ja) 改善された遺伝子サイレンシングのための組成物及び方法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251128